The France Genomics Market was valued at $23560.3 Million in 2025 and projected to reach to $40061.7 Million by 2030, representing a compound annual growth rate of 11.2%. France's genomics reagents, kits, and consumables market is positioned for substantial growth through 2030, supported by increasing healthcare expenditure on precision medicine and diagnostic innovation.
France's genomics reagents, kits, and consumables market is expanding at 11.2% CAGR, reaching $23.56 billion in 2025 and projected to grow to $40.06 billion by 2030, driven by increased adoption of genomic testing in French healthcare institutions.
French hospitals and diagnostic laboratories are increasingly integrating genomic sequencing into routine clinical practice, particularly for cancer genomics and rare disease diagnosis, boosting demand for specialized reagents and kits.
France's robust pharmaceutical and biotech research sector, concentrated in Paris and Lyon, drives significant consumption of genomics consumables for drug development, personalized medicine research, and academic genomic studies.
French government initiatives and EU funding programs supporting precision medicine and genomic research infrastructure are accelerating market growth and encouraging investment in genomics capabilities across public and private sectors.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.6% from 2025 to 2030 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 47.01 (2025) |
| Revenue Forecast (Billions) | ~USD 85.09 (2030) |
| Segments Covered | Offering, Type, Technology, End User, Study Type, Application |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABCAM PLC | United Kingdom | Private Company | Reagents (antibodies, proteins, peptides, biochemicals),Kits (conjugation, cellular activity, pathway tools, immunoassays),Instruments and tools-adjacent products, |
| AFFYMETRIX INC | United States | Private Company | Reagents,Kits,Instruments, |
| BECKMAN COULTER | United States | Private Company | Instruments (flow cytometers, centrifuges, capillary electrophoresis, liquid handlers, analyzers),Reagents & Kits (sample prep, library construction, single-cell PCR, immunoassay),Genome Profiling & Genomic Services, |
| CEPHEID INC. | United States | Private Company | Instruments (GeneXpert, SmartCycler),Reagents & Kits (Xpert tests and related consumables),Services (Genome profiling, bioinformatics, support), |
| CORNING, INC. | United States | Public Company | Reagents and Kits,Instruments and Lab Equipment,Labware and Specialty Surfaces for Genomics, |
| DECODE GENETICS | Iceland | Private Company | Reagents,Kits,Instruments, |
| GENOMIC HEALTH INC | United States | Private Company | Genomic-based diagnostic services (oncology),Genome profiling services beyond core oncology,Bioinformatics and data-related services, |
| UNILABS | Switzerland | Private Company | Reagents,Kits,Instruments, |
| MAXCYTE, INC | United States | Public Company | Instruments (ExPERT ATx, STx, GTx, VLx),Consumables (Processing Assemblies, buffers, accessories),Licensing and technology access, |
| DANAHER CORPORATION | United States | Public Company | Reagents and Kits,Instruments (Sequencing-adjacent, PCR, Flow Cytometry, Sample Prep),Services (Genome Profiling, Bioinformatics, Custom Development), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Instruments (sequencing-adjacent, PCR, flow cytometry, ISH platforms),Reagents and Kits,Genomics Services (Genome Profiling, CDMO, and Lab Services), |
| REVVITY | United States | Public Company | Reagents & Kits,Instruments,Genome Profiling Services, |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | United States | Public Company | Reagents,Kits,Instruments, |
| IQVIA INC. | United States | Public Company | Genomics Services – Genome Profiling & Central Labs,Bioinformatics & Real-World Genomics Analytics,Genomics-Enabled Clinical Research Services, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Reagents,Kits,Instruments, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Reagents,Kits,Instruments, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Reagents,Kits,Instruments, |
| PACBIO | United States | Public Company | Instruments (Revio, Sequel, Vega, Onso),Reagents & Kits (SMRT cells, prep, binding, sequencing kits),Services (Genome profiling, bioinformatics and related), |
| OXFORD NANOPORE TECHNOLOGIES PLC. | United Kingdom | Public Company | Instruments (MinION, GridION, PromethION family),Reagents & Kits,Genome Profiling & Sequencing Services, |
| TAKARA BIO INC. | Japan | Private Company | Reagents,Kits,Instruments, |
Abcam PLC is a United Kingdom-based private company founded in 1998 with 1,760 employees that develops and supplies research reagents and tools for the life sciences industry.
Affymetrix Inc. is a United States-based private company founded in 1991 with 1,150 employees focused on molecular biology and genomic analysis technologies.
Beckman Coulter is a United States-based private company founded in 1935 with 11,900 employees that manufactures and distributes laboratory instruments and diagnostic equipment.
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees that develops molecular diagnostic systems and point-of-care testing solutions.
Corning, Inc. is a United States-based public company founded in 1851 with 67,200 employees that manufactures specialty glass, ceramics, and laboratory equipment.
deCODE Genetics is an Iceland-based private company founded in 1996 with 331 employees focused on genomic research and genetic analysis.
Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees specializing in genomic-based diagnostic testing.
Unilabs is a Switzerland-based private company founded in 1987 with 1,897 employees providing clinical laboratory and diagnostic testing services.
MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating a diversified portfolio of businesses including life sciences and diagnostics.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees manufacturing analytical instruments and life sciences equipment.
Revvity is a United States-based public company founded in 1937 with 11,000 employees providing analytical instruments and life sciences solutions.
Laboratory Corporation of America Holdings is a United States-based public company founded in 1995 with 66,385 employees operating one of the largest clinical laboratory networks.
IQVIA Inc. is a United States-based public company with 93,000 employees providing clinical research, data analytics, and technology solutions to the pharmaceutical and healthcare industries.
Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services for drug development.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing and distributing life science research and clinical diagnostic products.
Eurofins Scientific is a Luxembourg-based public company founded in 1987 with 65,694 employees providing laboratory testing and analytical services across multiple industries.
PacBio is a United States-based public company founded in 2000 with 485 employees developing long-read DNA sequencing technologies.
Oxford Nanopore Technologies PLC. is a United Kingdom-based public company founded in 2005 with 1,316 employees specializing in nanopore-based DNA and RNA sequencing technologies.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees providing molecular biology reagents and biotechnology products.
Reagents, Kits, And Consumables include DNA extraction reagents, PCR kits, sequencing reagents, library preparation kits, and disposable laboratory materials used in genomic analysis workflows.
Reagents, Kits, And Consumables experience higher growth due to increased testing volume, repeated consumption per assay, continuous innovation in chemistry, and expanding clinical adoption of genomic testing.
Key drivers include NGS adoption, personalized medicine initiatives, expanded genetic screening programs, automation in laboratories, and cost reductions enabling broader accessibility of Reagents, Kits, And Consumables.
Reagents, Kits, And Consumables are formulated to optimize DNA/RNA quality, minimize contamination, and enhance signal-to-noise ratios, directly impacting the reliability and sensitivity of genomic assays.
North America and Europe lead in Reagents, Kits, And Consumables adoption, while Asia-Pacific demonstrates the fastest growth due to expanding healthcare infrastructure and increasing genomic testing initiatives.
This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global genomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the genomics market. The secondary sources used for this study include Nucleic Acids Research, Genome Biology, the International Journal of Genomics, the National Human Genome Research Institute (NHGRI), the International Chromosome and Genome Society (ICGS), Genome Canada, the European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, the Centre for Cellular & Molecular Biology (CCMB), São Paulo Research Foundation (FAPESP), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, World Bank, the World Health Organization (WHO), Eurostat, and Factiva; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.
After acquiring foundational knowledge about the global genomics market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from academic & research institutes, hospitals, clinics & diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the genomics market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:
After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Genomics is a branch of molecular biology that involves the study of the structure, function, evolution, and mapping of genomes. It applies the techniques of genetics, molecular biology, and bioinformatics to sequence, assemble, and analyze the function and structure of the genome of a selected organism for analysis. Genomics is widely used in diagnostics, drug discovery and development, animal and agricultural research, forensics, and aquaculture research, among others.
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Genomics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report